Novartis AG$154.41ABBV · NYSE
AbbVie sells prescription medicines and aesthetic products to patients, physicians, health systems and other healthcare customers. Its major businesses include immunology, led by Skyrizi and Rinvoq; neuroscience, including the migraine treatment Ubrelvy; and Allergan Aesthetics, including Botox Cosmetic. Immunology and neuroscience are currently the clearest growth engines, both posting double-digit growth in the reported second quarter, while aesthetics adds diversification. The company has moved beyond its former dependence on Humira and now markets multiple blockbuster products. AbbVie generated $61.2 billion of 2025 revenue and $4.2 billion of net income, versus $56.3 billion and $4.3 billion in 2024.
AbbVie fell $19.40, or 7.37%, from $263.20 to $243.80 over the measured week. Shares were essentially flat through July 29 before declining for four consecutive sessions, including heavier volume on August 3 and 4. The main catalyst was the second-quarter update: AbbVie beat earnings and revenue expectations and raised full-year revenue guidance by $300 million, but cut its 2026 EPS outlook because of the Apogee acquisition, which also increases research and development spending. Strong Skyrizi, Rinvoq, immunology and neuroscience growth therefore failed to offset dilution concerns. Regulatory news was constructive but secondary, with Canadian reimbursement support for Ubrelvy and FDA review of a Botox Cosmetic application.
Allergan Aesthetics Seeks Fifth FDA Approval For BOTOX Cosmetic In Facial ContouringAbbVie (ABBV) Q2 2026 Earnings Call TranscriptABBV Q2 Earnings Call Balances Growth With Apogee DilutionAbbVie Quietly Solved Its Biggest Problem—Now What?
